Sugi Predict

Sugi Predict / Compounds / SCHEMBL85511

SCHEMBL85511

SCHEMBL85511

CC(C)(C)OC(=O)N1CC(=O)C[C@@H]1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ PTPN1 P18031 2/20 0.38
▸ MMP2 P08253 1/20 0.36
▸ ANPEP P15144 1/20 0.36
▸ NFKB1 P19838 1/20 0.36
▸ NFKB2 Q00653 1/20 0.36
▸ RELA Q04206 1/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ HSD11B1 P28845 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ GPR119 Q8TDV5 1/20 0.35
▸ HDAC8 Q9BY41 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL204966 1.00 HSD17B10 (0.43) HSD17B10SMN1; SMN2PTPN1MMP2ANPEP
SCHEMBL204965 1.00 HSD17B10 (0.43) HSD17B10SMN1; SMN2PTPN1MMP2ANPEP
SCHEMBL17644197 0.88 ACE (0.43) PTPN1MMP2ANPEPGPR119HDAC8
SCHEMBL875282 0.87 PTPN1 (0.43) HSD17B10SMN1; SMN2PTPN1MMP2ANPEP
SCHEMBL31080852 0.87 PTPN1 (0.43) HSD17B10SMN1; SMN2PTPN1MMP2ANPEP
SCHEMBL13804335 0.87 CHRM2 (0.39) HSD17B10SMN1; SMN2PTPN1MMP2ANPEP
SCHEMBL13059380 0.87 CHRM2 (0.39) HSD17B10SMN1; SMN2PTPN1MMP2ANPEP
SCHEMBL877760 0.87 PTPN1 (0.43) HSD17B10SMN1; SMN2PTPN1MMP2ANPEP
SCHEMBL15829069 0.87 CHRM2 (0.39) HSD17B10SMN1; SMN2PTPN1MMP2ANPEP
SCHEMBL4497625 0.86 HSD17B10 (0.43) HSD17B10SMN1; SMN2PTPN1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026098560-A2 BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2026-05-15 — — WO disclosed
EP-4731216-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS Augustine Therapeutics (BE) 2026-04-29 — — EP disclosed
CN-114591212-B Human plasma kallikrein inhibitors 拜奥克里斯特制药公司 2025-01-28 — — CN disclosed
WO-2024261329-A1 HETEROARYL-AMINE COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS AUGUSTINE THERAPEUTICS (BE) 2024-12-26 — — WO disclosed
EP-4019022-B1 HUMAN PLASMA KALLIKREIN INHIBITORS BIOCRYST PHARM INC (US) 2024-01-31 — — EP disclosed
US-11807605-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-11807605-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
US-11807605-B2 Human plasma kallikrein inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2023-11-07 — — US disclosed
WO-2023042914-A1 PYRROLIDINE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-03-23 — — WO disclosed
CN-114751801-B Method for preparing deuterated amino acid ester by photocatalysis 安徽贵朋功能材料科技有限公司 2022-12-27 — — CN disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 — — EP disclosed
US-20040220238-A1 Pyrrolidine oxadiazole-and thiadiazole derivatives MERCK SERONO SA (CH) 2004-11-04 — — US disclosed
US-20040147511-A1 Pyrrolidine ester derivatives with oxytocin modulating activity MERCK SERONO SA (CH) 2004-07-29 — — US disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 — — WO disclosed
US-20030212012-A1 Pharmaceutically active pyrrolidine derivatives MERCK SERONO SA (CH) 2003-11-13 — — US disclosed
US-20030171309-A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors MERCK SERONO SA (CH) 2003-09-11 — — US disclosed
EP-1268418-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS Applied Research Systems ARS Holding N.V. (AN) 2003-01-02 — — EP disclosed
EP-1268419-A1 PYRROLIDINE DERIVATIVES USEFUL AS BAX INHIBITORS Applied Research Systems ARS Holding N.V. (AN) 2003-01-02 — — EP disclosed
WO-2001074769-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-10-11 — — WO disclosed
WO-2001072705-A1 PHARMACEUTICALLY ACTIVE PYRROLIDINE DERIVATIVES AS BAX INHIBITORS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-10-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212012-A1 Pharmaceutically active pyrrolidine derivatives OXTR, CNR1, PRLHR HSD17B10 1183/4885SMN1; SMN2 1513/4885PTPN1 2502/4885
US-20040220238-A1 Pyrrolidine oxadiazole-and thiadiazole derivatives OXTR, PRLHR, PGF HSD17B10 2124/4885SMN1; SMN2 2634/4885PTPN1 3934/4885
US-11807605-B2 Human plasma kallikrein inhibitors KLKB1, KLK5, KLK1 HSD17B10 1050/4885SMN1; SMN2 3221/4885PTPN1 2692/4885
US-20040147511-A1 Pyrrolidine ester derivatives with oxytocin modulating activity OXTR, OPRL1, OPRD1 HSD17B10 1284/4885SMN1; SMN2 1734/4885PTPN1 2726/4885
US-20030171309-A1 Pharmaceutically active pyrrolidine derivatives as bax inhibitors SUCNR1, PYCR1, GLS HSD17B10 1885/4885SMN1; SMN2 459/4885PTPN1 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.